. To elucidate the genetic architecture and understand the underlying disease mechanisms, we carried out a meta-analysis of allergic rhinitis in 59,762 cases and 152,358 controls of European ancestry and identified a total of 41 risk loci for allergic rhinitis, including 20 loci not previously associated with allergic rhinitis, which were confirmed in a replication phase of 60,720 cases and 618,527 controls. Functional annotation implicated genes involved in various immune pathways, and fine mapping of the HLA region suggested amino acid variants important for antigen binding. We further performed genome-wide association study (GWAS) analyses of allergic sensitization against inhalant allergens and nonallergic rhinitis, which suggested shared genetic mechanisms across rhinitis-related traits. Future studies of the identified loci and genes might identify novel targets for treatment and prevention of allergic rhinitis.
Allergic rhinitis, an inflammatory disorder of the nasal mucosa, is mediated by allergic hypersensitivity responses to environmental allergens 1 . It has substantial adverse effects on quality of life and health-care expenditures. The underlying causes of allergic rhinitis are still not understood, and prevention of the disease is not possible. The heritability of allergic rhinitis has been estimated to be more than 65% (refs 3,4 ). Seven loci have been associated with allergic rhinitis in GWAS on allergic rhinitis, and other loci have been suggested from GWAS on related traits such as self-reported allergy, asthma plus hay fever, or allergic sensitization [5] [6] [7] [8] [9] ; however only a few of these findings have been replicated.
We carried out a large-scale meta-GWAS on allergic rhinitis including a discovery meta-analysis of 16,531,985 genetic markers from 18 studies comprising 59,762 cases and 152,358 controls of primarily European ancestry (Supplementary Table 1 and cohortrecruitment details in Supplementary Note). We report the genetic heritability on the liability scale of allergic rhinitis to be at least 7.8% (assuming 10% disease prevalence), with a genomic inflation of 1.048 ( Supplementary Fig. 1 ). We identified 42 genetic loci with index markers below genome-wide significance (P < 5 × 10 One study (23andMe) had a proportionally large weight (~80%) in the discovery phase. Overall, there was good agreement between 23andMe and the other studies with respect to effect size and direction and regional association patterns (Supplementary Table 2 and Supplementary Figs. 4 and 5), and the genetic correlation was 0.80 (P < 2 × 10
−17
). The heterogeneity between 23andMe and the remaining studies was statistically significant (P < 0.05) for 7 of 42 loci, in most cases because of a smaller effect size in 23andMe. This finding was probably due to many non-23andMe studies using a more robust phenotype definition of doctor-diagnosed allergic rhinitis (Supplementary Table 3) , which tended to result in larger effect sizes (Supplementary Table 4 ).
The index markers from a total of 25 loci that had not previously been associated with allergic rhinitis or other inhalant allergy were carried forward to the replication phase. These markers included 16 loci that showed genome-wide-significant association in the discovery phase and evidence of association (P < 0.05) in both 23andMe and non-23andMe studies (Supplementary Table 2) , and an additional nine loci that were selected from the P-value stratum between 5 × 10 −8 and 1 × 10
, on the basis of enrichment of gene sets involved in immunological signaling (Supplementary Table 5 ). We sought replication in another ten studies with 60,720 cases and 618,527 controls. Of the 25 loci, 20 reached a Bonferroni-corrected significance threshold of 0.05 (P < 0.0019) in a meta-analysis of replication studies ( Fig. 1 (blue) and Table 2 ) and also reached genomewide significance in the combined fixed-effect meta-analysis of discovery and replication studies ( Table 2) . Evidence of heterogeneity was seen for one of these loci (rs1504215), which did not reach statistical significance in the random-effects model (0.95 (0.92; 0.97), P = 2.83 × 10 −7
; Supplementary Fig. 3) . A conditional analysis of top loci identified 13 additional independent variants at P < 1 × 10 −5
, four of which were genomewide significant (near WDR36, HLA-DQB1, IL1RL1, and LPP; Supplementary Table 6 and Supplementary Fig. 5 ).
To gain insight into the functional consequences of known and novel loci, we used a number of data sources, including: (i) 11 expression quantitative trait locus (eQTL) sets and one methylation quantitative trait locus (meQTL) set from blood and blood subsets; (ii) two eQTL sets and one meQTL set from lung tissue; and (iii) data on enhancer-promoter interactions in 15 different blood subsets. We found support for regulatory effects on coding genes for 33 of the 41 loci. Many loci showed evidence of regulatory effects across a wide range of immune-cell types (including B and T cells), whereas other loci seemed to be cell-type specific (Supplementary Table 7 ). Calculating the 'credible set' of markers for each locus through a Bayesian approach that selected markers likely to contain the causal disease-associated markers (Supplementary Table 8 ) and then looking up those markers in the Variant Effect Predictor database generated a list of 17 markers producing amino acid changes, including deleterious changes in NUSAP1, SULT1A1 and PLCL, as predicted by SIFT (Supplementary Table 9 ).
The major histocompatibility complex (MHC) on chromosome 6p contained some of the strongest association signals in the GWAS, including independent signals located around HLA-DQB and HLA-B. The top variant at HLA-DQB was an eQTL for several HLA genes, including HLA-DQB1, HLA-DQA1, HLA-DQA2, and HLA-DRB1 in immune and/or lung tissue, and the top variant at HLA-B was Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis A full list of authors and affiliations appears at the end of the paper.
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an eQTL for MICA (Supplementary Table 7 ). In addition, we found associations with several classical HLA alleles, including HLA-DQB1*02:02, HLA-DQB1*03:01, HLA-DRB1*04:01, and HLA-C*04:01, which were in weak linkage disequilibrium (LD) (r 2 < 0.1) with the GWAS top SNPs (Supplementary Tables 10 and 11) , and strong associations with well-imputed amino acid variants, including HLA-DQB1 His30 (P = 2.06 × 10 −28
, odds ratio (OR) = 0.91) and HLA-B Asp116/His116-/Leu116 (P = 6.00 × 10 Tables 12 and 13 ). Within HLA-DQB1, the amino acid variant was in moderate LD (r 2 = 0.71) with the GWAS top SNP and accounted for most of the SNP association (rs34004019, P = 2.18 × 10 −28
, OR = 0.88, conditional P = 1.35 × 10
−3
). Within HLA-B, the strongest associated amino acid variant was only in weak LD (r 2 = 0.23) with the top SNP and accounted for a small part of the SNP association (rs2428494, P = 3.99 × 10 −15
, OR = 1.07, conditional P = 3.23 × 10
−10
). Importantly, the strongest associated amino acid variants in HLA-DQB1 and HLA-B, respectively, were both located in the peptide-binding pockets with a high likelihood of affecting MHC-peptide interaction (Fig. 2) . MHC class II molecules, including HLA-DQ, are known for their roles in allergen binding and type Fig. 1 | Manhattan plot of the meta-GWAs discovery phase. Circular plot of P values, calculated from the two-tailed z score from an inverse-varianceweighted fixed-effect meta-analysis of association of 16,531,985 genetic markers with allergic rhinitis from the discovery phase, including 212,120 individuals. Only markers with P < 1 × 10 −3 are shown. Labels indicate the nearest gene name for the index marker in the locus (the marker with the lowest P value). Green labels indicate loci previously associated with allergy; blue labels indicate novel allergic rhinitis-associated loci; gray labels indicate novel loci that were not carried forward to the replication phase. Green line indicates the level of genome-wide significance (P = 5 × 10 −8 ).
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helper T cell (T H 2)-driven immune responses
10
; our results therefore suggest that the GWAS signal at this locus involves structural changes related to allergen binding properties. This effect might be in addition to gene-regulatory effects similar to those found for autoimmune disease 11, 12 . Most of the 20 loci not previously associated with allergic rhinitis implicate genes with a known role in the immune system, including IL7R ). Other loci implicated genes with no clear function in allergic rhinitis pathogenesis. These included one of the strongest associated loci in this meta-analysis at 12q24.31, with the top signal located between CDK2AP1 and C12orf65, and containing cis-eQTLs in blood and lung tissue for several genes and evidence of enhancer-promoter interaction with DDX55 in various immune cells (Supplementary Table 14 and further locus description in Supplementary Note). Concomitantly with the current study, a GWAS combining asthma, eczema, and allergic rhinitis was conducted 29 . Most (15/20) of the identified allergic rhinitis-associated loci in our study were also suggested in the previous, less specific GWAS 29 (as indicated in Table 2 ), whereas many suggested loci from the previous GWAS were not identified in our study. Asthma, eczema, and allergic rhinitis are related but distinct disease entities, often with separate disease mechanisms; for example, allergic sensitization is present in only 50% of children with asthma 30 and 35% of children with eczema 31 . Our results therefore complement those from the less specific 'atopic phenotype' GWAS 29 by pinpointing loci specifically associated and replicated in relation to allergic rhinitis.
Allergic rhinitis-associated loci were significantly enriched (P < 1 × 10 −5 ) in variants reported to be associated with autoimmune disorders. Reported autoimmune variants were located within 1 Mb of 31 (76%) of the 41 allergic rhinitis-associated loci. For 24 of these, an autoimmune top SNP was also associated with allergic rhinitis, and for 12 of these, the autoimmune top SNP was in LD (r 2 > 0.5) with the allergic rhinitis top SNP (Supplementary Table 15 ). For approximately half of these, the direction of the effect was the same for the autoimmune and allergic rhinitis top SNP, in line with findings from a previous study 32 , thus underlining the complex genetic relationship between allergic rhinitis and autoimmunity, which might involve shared as well as diverging molecular mechanisms.
Assessment of the enrichment of allergic rhinitis-associated variant burden in open chromatin, as defined by DNase-hypersensitive sites, showed a clear enrichment in several blood and immune-cell subsets, with the largest enrichment in T cells (CD3 expressing), B cells (CD19 expressing), and T and NK cells (CD56 expressing) (Fig. 3, Supplementary Table 16 and Supplementary Fig. 6 ). We also probed tissue enrichment by using gene-expression data from a wide number of sources and observed enrichment of allergic rhinitis-associated genes in blood and immune-cell subsets, as well as in tissues of the respiratory system, including the oropharynx and the respiratory and nasal mucosa (Supplementary Table 17) .
To explore biological connections and identify new pathways associated with allergic rhinitis, we combined all genes suggested from the eQTL and meQTL analyses, enhancer-promoter interactions, and localization within the top loci. The resultant prioritized gene set consisted of 255 genes, of which 89 (~36%) were 'Nearest genes' denotes the nearest up-and downstream gene (for intergenic variants with two genes listed) or surrounding gene (for intronic variants with one gene listed), with the exception of rs5743618, an exonic missense variant within TLR1. EA/OA, effect allele/other allele; EAF, effect-allele frequency. P values were calculated from two-tailed z scores from an inverse-variance-weighted fixed-effect meta-analysis. Het. P, P value for heterogeneity obtained from Cochrane's Q test.
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NATurE GENETicS Table 2 Fig. 7) . Overall, the full set was enriched in pathways involved in type 1 helper T cell (T H 1) and T H 2 activation (Fig. 4) , antigen presentation, cytokine signaling, and inflammatory responses (Supplementary Table 18 ). Using the 255 prioritized genes in combination with the STRING database to identify proteins interacting with the proteins encoded by the high-priority genes, we demonstrated a high degree of interaction at the protein level, and several of these proteins, including TNFSF11, NDUFAF1, PD-L1, IL-5, and IL-13, are targets of approved drugs or drugs in development (Fig. 4) .
Allergic rhinitis is strongly correlated with allergic sensitization (presence of allergen-specific IgE), but sensitization is often present without allergic rhinitis, thus suggesting that specific mechanisms determine the progression from sensitization to disease. We therefore conducted a GWAS on sensitization to inhalant allergens, comprising 8,040 cases and 16,441 controls from 13 studies (Supplementary Table 1 ), in what is, to our knowledge, the largest GWAS on allergic sensitization to date 7 . A total of ten loci reached genome-wide significance, including one novel locus near FASLG (Supplementary Table 19 ). The genetic heritability on the liability scale was 17.75% (10% prevalence), a value considerably higher than the heritability of allergic rhinitis and consistent with a more homogeneous phenotype. Look-up of top allergic rhinitis-associated loci in the allergic-sensitization GWAS demonstrated high agreement: 40 of the 41 allergic rhinitis markers showed the same direction of effect, and 28 also showed nominal significance for allergic sensitization (Supplementary Table 20 ). This result suggests that allergic , located close to P6 with a distance of 6 Å to the peptide (excluding the peptide side chain). The protective amino acid variant at this location in relation to allergic rhinitis was histidine, whereas the risk variant was serine. Histidine is positively charged and has a large aromatic ring, whereas serine is not charged and not aromatic. Therefore, this alteration results in a substantial change in the bindingpocket environment. b, The strongest allergic rhinitis-associated amino acid variants in HLA-B (MHC class I) were HLA-B Asp116/His116-/Leu116, located close to P9 with a distance of 7 Å to the peptide (excluding the peptide side chain). The proximity to the bound peptide for both variants indicates that they are likely to affect the MHC-peptide interaction and thereby affect which peptides are presented. 
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rhinitis and allergic sensitization share biological mechanisms, and that allergic-sensitization loci generally affect systemic allergic sensitization. We compared genetic pathways of allergic rhinitis and allergic sensitization by using the DEPICT tool, which showed overlap in enriched pathways but also differences among the top gene sets: allergic rhinitis gene sets were characterized by B cell, T H 2, and parasite responses, whereas allergic-sensitization gene sets were characterized by a broader activation of cells ( Supplementary Fig. 8 and Supplementary Tables 21 and 22) .
Nonallergic rhinitis, defined as having rhinitis symptoms without evidence of allergic sensitization, is a common but poorly understood disease entity 33 . We performed what is, to our knowledge, the first GWAS on this phenotype, with the goal of identifying specific rhinitis mechanisms. The analysis included 2,028 cases and 9,606 controls from nine studies but did not identify any risk loci at the genome-wide-significant level. Comparison with the allergic rhinitis results suggested some overlap in susceptibility loci (Supplementary  Note and Supplementary Table 23) .
We estimated the proportion of allergic rhinitis in the general population that was attributable to the 41 identified allergic rhinitis-associated loci and obtained a conservative populationattributable risk-fraction estimate of 39% (95% confidence interval (CI) 26-50%), by considering the 10% of the population with the lowest genetic-risk scores to represent an 'unexposed' group. The allergic rhinitis prevalence plotted by genetic-risk score ( Supplementary Fig. 9 ) showed a prevalence approximately two times higher in the 7% of the population with the highest risk score than the 7% with the lowest risk score. Blue nodes represent drugs from the ChEMBL drug database. Edges represent very high-confidence interactions from the STRING database (for locuslocus interactions) and drug-target evidence (for drug-locus interactions). Red borders indicate genes with protein products that were significantly enriched in the 'T H 1 and T H 2 activation' pathway (-log(P) > 19.1) from ingenuity pathway analysis.
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Finally, we investigated the genetic correlation of allergic rhinitis with allergic sensitization, asthma 34 , and eczema 35 by using LD-score regression. There was a strong correlation between allergic rhinitis and allergic sensitization (r 2 = 0.73, P < 2 × 10 −34
), a moderate correlation with asthma (r 2 = 0.60, P < 3 × 10 −14
), and a weaker correlation with eczema (r 2 = 0.40, P < 2 × 10
−7
). We tested the identified allergic rhinitis-associated loci for association with allergic rhinitis in non-European cohorts, which showed only a nominally significant association for one locus, but this analysis had limited statistical power, owing to population sizes (Supplementary Table 24 ).
In conclusion, we expanded the number of established susceptibility loci for allergic rhinitis and highlighted the involvement of allergic rhinitis-susceptibility loci in diverse immune-cell types and both innate and adaptive IgE-related mechanisms. Future studies of novel allergic rhinitis-associated loci might identify targets for the treatment and prevention of this disease.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0157-1. 
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Methods
Phenotype definition. Allergic rhinitis. Cases were defined as individuals who had ever received a diagnosis or experienced symptoms of allergic rhinitis, on the basis of available phenotype definitions in the included studies (Supplementary  Table 3 and cohort-recruitment details in Supplementary Note). All relevant ethical regulations were followed, as specified in relation to the individual studies in the Supplementary Note. To maximize numbers and optimize statistical power, we did not require doctor-diagnosed allergic rhinitis or verification by allergic sensitization. This approach was confirmed by a sensitivity analysis in 23andMe on the basis of association with known risk loci for allergic rhinitis (data not shown). Controls were defined as individuals who had never received a diagnosis or experienced symptoms of allergic rhinitis.
Allergic sensitization. We considered specific IgE production against inhalant allergens without restricting by assessment method or type of inhalant allergen. Cases were defined as individuals with objectively measured sensitization against at least one of the inhalant allergens tested for in the respective studies, and controls were defined as individuals who were not sensitized against any of the allergens tested for. We included sensitization assessed by skin reaction after puncture of the skin with a droplet of allergen extract (SPT) and/or by detection of the levels of circulating allergen-specific IgE in the blood. The SPT wheal-diameter cutoffs were ≥ 3 mm for cases and < 1 mm for controls. To optimize case specificity and the correlation between methods, we chose a high cutoff of specific IgE levels for cases (0.7 IU/ml) and a low cutoff for controls (0.35 IU/ml).
Nonallergic rhinitis. Cases were defined as individuals with current allergic rhinitis symptoms (within the previous 12 months) and no allergic sensitization (negative specific IgE (< 0.35 IU/ml) and/or negative skin-prick test (< 1 mm) for all allergens and time points tested).
Controls were defined as individuals who had never had symptoms of allergic rhinitis and showed no allergic sensitization (negative specific IgE (< 0.35 IU/ml) and/or negative skin-prick test (< 1 mm) for all allergens and time points tested)
For all three phenotypes, we combined data from children and adults but chose a lower age limit of 6 years, because allergic rhinitis and sensitization status at younger ages show poorer correlation with status later in life, owing to both transient symptoms/sensitization status and frequent development of symptoms/ sensitization during late childhood.
GWAS quality control and cohort summary-data harmonization. For allergic rhinitis, allergic sensitization, and nonallergic rhinitis, data were imputed separately for each cohort with the 1000 Genomes Project (1KGP) phase 1, version 3 release, and the genome-wide association analysis was adjusted for sex and, if necessary, for age and principal components (Supplementary Table 3 ). All studies included individuals of European descent, except Generation R and RAINE, which comprised a mixed, multiancestral population. We used EasyQC v. 9.2 (ref. 36 ) for quality control and marker harmonization for cohort-level meta-GWAS summary files. Cohort data were harmonized to genome build GRCh37 and were checked against the 1KGP phase 3 reference-allele frequencies for processing problems. GWAS summary 'karyograms' were visually inspected to catch cohorts with incomplete data. Distributions of estimate coefficients and errors, as well as plots of standard error versus sample size and of P value versus Z score, were inspected for each cohort for systematic errors in statistical models. Ambiguous markers that were nonunique in terms of both genomic position and allele coding were removed. A minimum imputation score of 0.3 (r 2 ) or 0.4 (proper_info) was required for markers. A minimum minor-allele count of 7 was required for each marker in each cohort, as suggested by the GIANT consortium and EasyQC.
Meta-analysis. For allergic rhinitis, allergic sensitization, and nonallergic rhinitis, meta-analysis for the discovery phase was conducted with GWAMA 37 with an inverse-variance-weighted fixed-effect model with genomic-control correction of the individual studies. Each locus is represented by the variant showing the strongest evidence within a 1-Mb buffer. Loci were inspected visually by plotting genomic neighborhood and coloring for 1KGP r 2 values. From the pool of genome-wide-significant markers in the discovery, one locus with index marker rs193243426 without a credible LD structure was removed from further analysis (Supplementary Fig. 10 ). Heterogeneity was assessed with Cochran's Q test.
Meta-analysis of replication candidates from the allergic rhinitis discovery phase was carried out in R version 3.4.0 and the meta package version 4.8-2 with an inverse-variance-weighted fixed-effect model. For a subset of markers, cohorts reported suitable proxies (r 2 > 0.85), and followed-up markers were not present or had insufficient imputation or genotyping quality (Supplementary Table 25 ).
Gene-set-overrepresentation analysis, discovery phase. To facilitate the selection of biologically relevant discovery candidates in the sub-genome-wide significant stratum (5 × 10 −8 < P < 1 × 10 −6 ), we used a custom algorithm for gene-set-overrepresentation analysis implemented in R, with a scoring and permutation regime modeled after MAGENTA 38 . Genes with lengths less than 200 bp, with copies on multiple chromosomes, and with multiple copies on the same chromosome more than 1 Mb apart were removed from analysis. Gene models (GENCODE v 19) were downloaded from the UCSC Table Browser 39 and expanded 110 kb upstream and 40 kb downstream, similarly to the MAGENTA procedure. The HLA region was excluded from analysis (chromosome 6: 29691116-33054976). Similarly to the MAGENTA procedure, gene scores were adjusted for the number of markers per gene, gene width, recombination hotspots, genetic distance, and number of independent markers per gene, all with updated data from the UCSC Table Browser. For the gene-set-overrepresentation permutation calculation, gene sets from the MSigDB collections c2, c3, c5, c7, and hallmark were included 40 . A MAGENTA-style enrichment cutoff at 95% was used. Gene sets with FDR < 0.05 were considered.
Conditional analyses.
To identify additional independent markers at each discovery genomic region, we used genome-wide complex trait analysis (GCTA) v. 1.26.0 (ref. 41 ). Within a window of ± 1 Mb of each discovery-phase index marker, all markers were conditioned on the index by using the --cojo-cond feature of GCTA with default parameters. Plink v. 1.90b3.42 (ref. 42 ) was used to calculate r 2 for GCTA with the UK10K full genotype panel 43 as a reference. A total of 42 of 52 markers from the full discovery phase were present in UK10K. Because a MAFdependent inflation of conditional P values was observed (data not shown), only conditional markers with MAF ≥ 10% were selected.
Locus definition and credible sets for VEP annotation. Discovery loci were defined as index markers extended with markers in LD (r 2 ≥ 0.5), on the basis of 1KGP phase 3. Protein-coding gene transcript models (GENCODE v. 24) were downloaded from the UCSC Table Browser, and the nearest upstream and downstream genes, as well as all genes within the extended loci, were annotated. Credible sets for each locus were calculated with the method of Morris 44 . LD was calculated for each discovery index variant within ± 500 kb, and markers with r 2 < 0.1 were excluded. For the remaining markers, the Bayesian factor (ABF) values and the posterior probabilities (PostProb) were calculated, and cumulative posterior probability values were generated on the basis of ranking markers on ABF. Finally, variants were included in the 99%-credible set until the cumulative posterior probability was ≥ 0.99.
Credible sets for each locus were annotated with information on mutation effects in coding regions by using the Variant Effect Predictor (VeP) REST API 45 , exporting only the nonsynonymous substitutions.
GWAS-catalog lookup.
For annotation of markers with identification in previous GWA studies, the GWAS catalog was downloaded from NHGRI-EBI (v.1.0.1, 28 November 2016). For this analysis, allergic rhinitis-associated loci were lifted from genomic build GRCh37 to GRCh38 and extended with ± 1 Mb in each direction before being overlapped with GWAS-catalog annotations. Relevant GWAS-catalog overlap traits were binned into the trait groups 'allergic rhinitis' , 'asthma' , 'autoimmune' , 'eczema' , 'infectious diseases' , 'lung-related traits' , and 'other allergy' . One million random genomic intervals of the same length (2 Mb) were obtained to generate a background overlap distribution, and P values were calculated from this background.
Classical HLA-allele analysis. Analyses of imputed classical HLA alleles were performed in the 23andMe study (AR discovery population) comprising 49,180 individuals with allergic rhinitis and 124,102 controls.
HLA imputation was performed with HIBAG v. 1.2.3 (ref. 46 ). We imputed allelic dosage for HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQA1, HLA-DQB1, and HLA-DRB1 loci at four-digit resolution with the default settings of HIBAG, for a total of 292 classical HLA alleles.
Using an approach suggested by de Bakker 47 , we downloaded the files mapping HLA alleles to amino acid sequences from https://www.broadinstitute.org/mpg/ snp2hla/ and mapped our imputed HLA alleles at four-digit resolution to the corresponding amino acid sequences; in this way, we translated the imputed HLA allelic dosages directly to amino acid dosages. We encoded all amino acid variants in the 23andMe European samples as 2,395 biallelic amino acid polymorphisms, as previously described 48 . Similarly to the SNP imputation, we measured imputation quality by using r 2 , which is the ratio of the empirically observed variance of the allele dosage to the expected variance, assuming Hardy-Weinberg equilibrium.
To test associations among imputed HLA alleles, amino acid variants, and phenotypes, we performed logistic regression using the same set of covariates used in the SNP-based GWAS. We applied a forward stepwise strategy within each type of variant to establish statistically independent signals in the HLA region. Within each variant type, we first identified the most strongly associated signals (lowest P value) and performed forward iterative conditional regression to identify other independent signals. All analyses were controlled for sex and five principal components of genetic ancestry. The P values were calculated with a likelihood-ratio test. Table 10) and was based on X-ray structures from the Protein Data Bank (PDB) 49 . To find
